Researchers track lung cancer care in china
NCT ID NCT07316062
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 5 times
Summary
This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are given—researchers simply review existing data to learn about current care patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Stage I-III at initial NSCLC diagnosis * Aged ≥18 years at first diagnosis of NSCLC * Timeframe of NSCLC diagnosis: For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027 Exclusion Criteria: * NSCLC is not the primary cancer diagnosis * Patients with a recent history of other tumor or concurrent other tumor * Patients participating in interventional clinical trials at time of initial diagnosis * Patients with positive pregnancy status at the time of diagnosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small-cell lung are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Research Site
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a two-drug combo outsmart resistant lung cancer?
- Timing is everything: new study seeks best sequence for brain metastases treatment
- Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
- New hope for advanced cancers? pfizer launches early trial of PF-08046033
- New hope for lung cancer patients whose current drug stops working
- New lung cancer drug shows promise in early trial